News >

NICE Recommends Ixazomib for Multiple Myeloma Through CDF

Jason Harris
Published: Tuesday, Dec 19, 2017

blood cells The United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance recommending ixazomib (Ninlaro) in for patients with relapsed/refractory multiple myeloma.1

= .02). The median duration of response was 20.5 months with ixazomib versus 15.0 months in the control arm.

References

  1. NICE.org/uk. Final appraisal determination: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. https://www.nice.org.uk/guidance/gid-ta10043/documents/html-content-3. Updated December 19, 2017. Accessed December 19, 2017.
  2. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621-1634.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x